Cannabinoids, Neural Implants, and CNS: Where First-in-Human Is Actually Going

Brazil's RDC 837/2023 device exemption, IN 433/2026 expanding the radiopharmaceutical list from 33 to 57 compounds, the LGPD pre-enrollment data governance gate, the CLINERGY Serra site signal, and a fresh batch of FIH sponsor prospects (Sidewinder, Marvel, Vivatides, Syneron Bio) reshaping the LATAM clinical research pipeline.

Brazil · Radiopharmaceuticals · Neurotechnology · CNS

Cannabinoids, Neural Implants, and CNS: Where First-in-Human Research Is Headed Next

bioaccess(R) | Global Trial Accelerators(TM) | Fast-Tracking First-in-Human Trials, Anywhere

Three therapeutic frontiers that would have been considered fringe a decade ago -- cannabinoids, implantable muscle-machine interfaces, and central nervous system (CNS) drug development -- are now reshaping where sponsors direct their early-phase research dollars. This week's briefing examines the regulatory, clinical, and operational shifts making these frontiers viable at scale, and what they mean for sponsors planning first-in-human (FIH) programs.

In This Issue

Brazil's new medicinal cannabis framework opens a formal clinical research pathway for cannabinoid therapeutics.
Phantom Neuro is advancing its muscle-machine interface prosthetic toward first-in-human studies.
Gary Zammit of Clinilabs Drug Development explains why CNS trials need new approaches to recruitment, endpoints, and patient engagement.
Technical translation is emerging as a make-or-break infrastructure layer for cross-border Latin American trials.
Underlying all of it: whether the region's clinical research infrastructure can keep pace with the science.

Brazil's Cannabis Framework Creates a Formal Research Pathway

Brazil's health regulator ANVISA approved a comprehensive regulatory framework for medicinal cannabis, providing greater clarity on cultivation, importation, manufacturing, and clinical research. For sponsors developing cannabinoid-based therapeutics, the framework establishes a structured environment in which early-phase trials can proceed under defined rules rather than regulatory ambiguity.

Why It Matters: The pharmaceutical and research community has long operated in a gray zone around cannabinoid clinical development in Latin America. Brazil is now one of the few emerging markets offering a formal, research-compatible pathway. Sponsors with cannabinoid FIH or proof-of-concept programs should evaluate Brazil alongside traditional North American and European sites.

Phantom Neuro Advances Toward First-in-Human for Muscle-Machine Interface

Phantom Neuro is advancing clinical development of an implantable sensor system designed to translate muscle signals into precise prosthetic control. The technology targets amputees seeking more natural and responsive control of advanced prosthetics, with potential applications extending into broader neurotechnology and assistive-device categories.

The program sits at the intersection of implantable-device complexity and emerging neurotechnology demand. Early feasibility and first-in-human study design will determine how quickly the company can generate the safety and performance data required for pivotal programs.

What to Watch: FIH study design and safety endpoints, performance data on muscle-signal translation, and geographic decisions on trial execution. The complexity of implantable neural devices typically favors jurisdictions with established FIH pathways and experienced sites -- a profile that increasingly includes Latin American markets with risk-stratified regulatory frameworks.

Advance Your First-in-Human Trials with Confidence

Does your company need accelerated first-in-human clinical trial results? bioaccess(R) partners with Medtech, Biopharma, and Radiopharma startups worldwide to deliver faster approvals and lower costs in Latin America.

Leverage 20+ years of expertise across Medtech, Biopharma, and Radiopharma first-in-human trials
Navigate complex LATAM regulatory landscapes with confidence
Get tailored support for study design, approvals, site selection, and patient recruitment

Bring your innovations to market faster with Latin America's first-in-human trial experts.

Schedule your first-in-human trial consultation at bioaccessla.com.

CNS Trials Demand a Different Operating Model

Gary Zammit, President and CEO of Clinilabs Drug Development Corporation and a leading voice in sleep medicine, joined the Global Trial Accelerators(TM) podcast to discuss the operational realities of CNS-focused clinical research. His central argument: CNS trials face recruitment, endpoint, and patient-engagement challenges that differ materially from other therapeutic areas -- and programs that succeed are typically those that combine scientific rigor with flexible trial execution.

The observation is particularly relevant for Latin American sites. CNS programs in insomnia, depression, PTSD, and neurodegenerative disease often benefit from patient populations that are both treatment-naive and accessible through established tertiary-care networks -- a profile that several Latin American sites can provide at lower cost and higher retention than traditional North American sites.

Bottom Line: CNS sponsors considering multi-country Phase I and Phase II programs should factor patient-recruitment dynamics and site flexibility into their geographic strategy from the earliest protocol-design stages -- not as a post-IND operational fix.

Technical Translation: The Hidden Infrastructure Layer for LATAM Trials

As sponsors expand into Colombia, Mexico, Argentina, and other Spanish-speaking markets, the accuracy of technical-file translation is emerging as a critical determinant of trial-startup speed. Clinical protocols, informed-consent forms, investigator brochures, and regulatory submissions must meet country-specific requirements. Poor translation introduces regulatory risk, delays site activation, and complicates communication with investigators and patients.

What to Focus On: Sponsors should treat technical translation as a pre-study startup item rather than a tactical cost. Engaging qualified regulatory translators during protocol finalization -- not after CRO selection -- can prevent multi-week delays in ethics-committee review and regulatory authorization. For studies targeting three or more Latin American countries, translation quality becomes an operational risk factor comparable to site selection.

Key Takeaways This Week

Brazil's new cannabis regulatory framework creates a formal clinical research pathway for cannabinoid therapeutics -- a rare development in emerging markets.
Phantom Neuro's muscle-machine interface prosthetic is advancing toward FIH, reflecting growing sponsor interest in implantable neurotechnology.
CNS clinical research requires flexible trial execution, specialized endpoints, and patient populations that Latin American sites are increasingly able to provide.
Technical translation is a make-or-break infrastructure layer for multi-country Latin American trials -- not a commodity service.
The diversity of new FIH frontiers underscores why risk-stratified regulatory pathways and experienced site networks are now strategic differentiators.
Sponsors developing advanced therapeutics should evaluate Latin America alongside traditional North American and European FIH destinations at the earliest strategy stage.

---

bioaccess(R) | Fast-Tracking First-in-Human Trials, Anywhere.

← All Global Trial Accelerators editions · Contact bioaccess®